KU Hematology & Medical Oncology Review 2019

 

KU Hematology & Medical Oncology Review 2019
R

KU ASCO GU 2019 Updates: Enzalutamide vs. Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer and Enfortumab in Metastatic Bladder Cancer

By KU Hematology & Medical Oncology Review 2019 FEATURING Rahul Parikh
By KU Hematology & Medical Oncology Review 2019 FEATURING Rahul Parikh
847 views
August 22, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

20:14
Exelixis

Hypothetical Patient Case: RAI-R Metastatic Differentiated Thyroid C…

Feat. R. Alter, R. Shameem

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
Genitourinary
11:59

KU ASCO GU 2019 Updates: Enzalutamide vs. Apalutamide in Metastatic …

KU Hematology & Medical Oncology Review 2019

R. Parikh

847 views
11:41

KU ASCO 2019 Updates: VEGF-TKI and/or PD-1/PD-L1 in Metastatic Renal…

KU Hematology & Medical Oncology Review 2019

R. Parikh

178 views